Two Phase III clinical studies showed that cardiac sympathetic nerve imaging using the AdreView radiopharmaceutical might help determine patients' risk of cardiac death and cardiac arrhythmias, said GE Healthcare, the maker of the radiopharmaceutical. The two trials make up the ADMIRE-HF trial, which was undertaken in 96 centers across Europe and North America.

Related Summaries